BSH 2018 | Accelerating patient outcomes in lymphoma
While there has been a range of new therapeutic options emerging for lymphoma, this introduces the challenge of assessing them quickly yet thoroughly. However, a consequence of rapid development is the neglection of rigorous investigations like randomized controlled trials. Here, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, from Oxford University Hospitals NHS Foundation Trust, Oxford, UK, describes the key ways to accelerate patient outcomes, including the use of a strong biological basis for therapies and involving statisticians when designing clinical studies. Speaking from the British Society for Haematology (BSH) 2018 Annual Meeting in Liverpool, UK, Dr Collins discusses the option of continuous reassessment models for clinical trials compared with the traditional 3+3 dose-escalation design.
Get great new content delivered to your inboxSign up